Clinical Trials Logo

Clinical Trial Summary

Conversion disorder refers to impaired voluntary motor or sensory functions that are not compatible with a well-known neurological condition. This disorder affects up to 30% of hospitalized patients in neurology departments and symptoms persist in 35% of patients after 12 years of evolution. Despite a poor prognosis, no treatments have been validated to date. The development of non-invasive brain stimulation techniques has allowed the creation of treatments focused on dysfunctional brain regions associated with motor conversion disorder. Hypoactivation of prefrontal dorso-lateral cortex underlies the course of functional motor symptoms. Results of the HYCORE study conducted at Nîmes University Hospital (including 20 patients, clinicaltrial.gov NCT02329626) confirmed these results and related hypoactivation of PFDLC to persistent motor disability at 3 months and 6 months follow-up. Activation of the PFDLC could restore executive control and thus promote the recovery of motor symptoms. However, in most repeated Transcranial Magnetic Stimulation (rTMS) the primary motor areas were targeted and the clinical improvement was related to self-suggestion induced by the motor response produced. Among the different techniques, transcranial Direct Current Stimulation (tDCS) is a medical neuromodulation device that delivers a direct, low-intensity electric current to cortical areas, facilitating neuronal activity. Recently, PFDLC stimulation via tDCS has been used to treat several neuropsychiatric disorders and shown to be effective in depression. In addition, this technique has several advantages compared to rTMS: its use is simpler and costs 5 to 8 times less, the device is portable and there is no titration procedure. The tolerance of the tDCS is also better with no risk of epileptic seizure, neuronal depolarization being absent.


Clinical Trial Description

Conversion disorder, also called "functional neurological disorder" (DSM-5), refers to impaired voluntary motor or sensory functions that are not compatible with a well-known neurological condition. This disorder affects up to 30% of hospitalized patients in neurology departments (Carson et al. 2000) and the symptoms persist in 35% of patients after 12 years of evolution (Stone et al. 2003). Despite a poor prognosis, no treatments have been validated to date. The development of non-invasive brain stimulation techniques has allowed the creation of focused treatments on dysfunctional brain regions associated with motor conversion disorder. A hypoactivation of prefrontal dorso-lateral cortex (PFDLC) underlies the course of functional motor symptoms (Spence et al. 2000); (Voon et al.2011); (Conejero et al. 2017). Results of the HYCORE study that the investigators conducted at Nîmes University Hospital (including 20 patients, clinicaltrial.gov NCT02329626) confirmed these results and related hypoactivation of PFDLC to persistent motor disability at 3 months and 6 months follow-up. Activation of the PFDLC could restore executive control and thus promote the recovery of motor symptoms. However, in the majority of repeated Transcranial Magnetic Stimulation (rTMS) the primary motor areas were targeted (Pollak et al. 2014) and the clinical improvement was related to self-suggestion induced by the motor response produced. Among the different techniques, transcranial Direct Current Stimulation (tDCS) is a medical neuromodulation device that delivers a direct, low-intensity electric current to cortical areas, facilitating neuronal activity. Recently, PFDLC stimulation via tDCS has been used to treat several neuropsychiatric disorders and shown to be effective in depression. In addition, this technique has several advantages compared to rTMS: its use is simpler and costs 5 to 8 times less, the device is portable and there is no titration procedure. The tolerance of the tDCS is also better with no risk of epileptic seizure, neuronal depolarization being absent. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04097184
Study type Interventional
Source Centre Hospitalier Universitaire de Nimes
Contact Ismael CONEJERO, Dr.
Phone 07 70 21 62 38
Email ismael.conejero@gmail.com
Status Recruiting
Phase N/A
Start date March 5, 2021
Completion date September 2025

See also
  Status Clinical Trial Phase
Completed NCT02275000 - Feasibility Study of Physiotherapy for Functional Motor Symptoms N/A
Completed NCT00971360 - Cytokine Levels in Conversion Disorder N/A
Completed NCT00835627 - Treatment Trial for Psychogenic Nonepileptic Seizures Phase 4
Active, not recruiting NCT01422278 - Rehabilitation of Conversion Gait Disorder Phase 1/Phase 2
Active, not recruiting NCT03441867 - Neuroimaging Biomarker for Seizures N/A
Completed NCT03398070 - Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders
Completed NCT02102906 - TMS and Attentional Bias in Functional Motor Disorder N/A
Completed NCT02325544 - Comparing Different Treatments in Reducing Dissociative Seizure Occurrence N/A
Terminated NCT02764476 - Embodied Virtual Reality Therapy for Functional Neurological Symptom/ Conversion Disorder N/A
Recruiting NCT05323344 - Metacognitive Therapy and Neuro-physiotherapy as a Treatment for Functional Movement Disorders N/A
Completed NCT05219006 - Ketogenic Diet Effects on the Frequency of Non Epileptic Seizures N/A
Completed NCT02329626 - Metabolic Anomolies Associated With the 6 Month Clinical Evolution of Patients Suffering From Motor Conversion Disorder
Recruiting NCT05943652 - Observational Study on "Functional Overlay" in Patients With Movement Disorders
Completed NCT00159965 - Treatments for Psychogenic Nonepileptic Seizures (NES) Phase 4
Completed NCT05305014 - Contribution of Inflammation and Neuronal Integrity Markers in Patients With First-episode Conversive Motor Disorder